Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study.
Jeong Eun LeeSoon Ok LeeJeonghun HeoDong Wan KimMi Ran ParkHyunjin SonDongkeun KimKye-Hyung KimShinwon LeeSun Hee LeePublished in: Antiviral therapy (2021)
Based on our study results, HCQ shows no apparent advantage compared to LPV/r for preventing progression to severe disease in patients with COVID-19.